Delivery Order SPE2DR25D2014-SPE2DR26FA2J3
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $4,259.60 delivery order on October 23, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens, with completion scheduled for October 24, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $3,173.46 to AmerisourceBergen Drug Corp for Novolog 100 Unit/ML FlexPen 3ML insulin pens on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a $5,676.56 delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This competitively awarded, firm fixed-price contract carries an ultimate completion date of October 21, 2025, and represents a direct procurement under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,853.05 on August 7, 2025, for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. As a child order under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,022.69. This firm fixed-price delivery order represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The insulin pens are to be...
- The Defense Logistics Agency awarded a $3,891.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Novolog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of October 31, 2025. This delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens, with a ceiling value of $1,633.44 and completion targeted for December 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $5,262.89 on August 22, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,041.80 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with performance completed in Conshohocken, Pennsylvania. This is a firm fixed-price, non-set-aside contract awarded on January 9, 2026, with an ultimate completion date of January 12, 2026. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FA2J3Delivery Order
The Defense Logistics Agency awarded a $5,189.93 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of January 14, 2026, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 comprehensive pharmaceutical supply vehicle valued through December 2031 that supports military healthcare programs globally. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on supporting military and veteran healthcare systems through the Defense Logistics Agency. The parent entity, Cencora, Inc., competes on a full and open basis for federal contracts and maintains extensive experience delivering specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This specific delivery order represents a routine task order under the larger pharmaceutical prime vendor agreement, enabling efficient fulfillment of essential insulin products required by military treatment facilities and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 1/12/26 |